The estimated Net Worth of Roger M Perlmutter is at least $51.3 Milion dollars as of 8 November 2018. Roger Perlmutter owns over 225,443 units of Merck & Co Inc stock worth over $42,098,226 and over the last 21 years he sold MRK stock worth over $0. In addition, he makes $9,223,350 as Executive Vice President a President - Merck Research Laboratories at Merck & Co Inc.
Roger has made over 4 trades of the Merck & Co Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 225,443 units of MRK stock worth $10,140,426 on 8 November 2018.
The largest trade he's ever made was exercising 225,443 units of Merck & Co Inc stock on 8 November 2018 worth over $10,140,426. On average, Roger trades about 7,706 units every 116 days since 2003. As of 8 November 2018 he still owns at least 366,997 units of Merck & Co Inc stock.
You can see the complete history of Roger Perlmutter stock trades at the bottom of the page.
Dr. Roger M. Perlmutter M.D. Ph.D. is no longer serves as Executive Vice President, President - Merck Research Laboratories of the Company effective 1/1/2021. He is responsible for the Company’s global research and development efforts. Dr. Perlmutter was executive vice president and head of R&D at Amgen Inc. from January 2001 to February 2012. During his tenure, Dr. Perlmutter oversaw the development and subsequent approval of a number of novel biologic and small molecule medicines in the areas of cancer, endocrinology, hematology, inflammation and osteoporosis. Prior to joining Amgen, he was executive vice president of worldwide basic research and preclinical development at Merck. He joined Merck as a senior vice president in February 1997. Before assuming leadership roles in industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington, where he also served as chairman of the Department of Immunology and was a Howard Hughes Medical Institute investigator. He is a Fellow of the American Academy of Arts and Sciences and an elected Fellow of the American Association for the Advancement of Science. Dr. Perlmutter graduated from Reed College in 1973 and received his M.D. and Ph.D. degrees from Washington University in St. Louis in 1979.
As the Executive Vice President a President - Merck Research Laboratories of Merck & Co Inc, the total compensation of Roger Perlmutter at Merck & Co Inc is $9,223,350. There are 1 executives at Merck & Co Inc getting paid more, with Kenneth Frazier having the highest compensation of $27,648,500.
Roger Perlmutter is 68, he's been the Executive Vice President a President - Merck Research Laboratories of Merck & Co Inc since 2013. There are 2 older and 24 younger executives at Merck & Co Inc. The oldest executive at Merck & Co Inc is Thomas Cech, 73, who is the Independent Director.
Roger's mailing address filed with the SEC is C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 15 years, insiders at Merck & Co Inc have traded over $138,980,380 worth of Merck & Co Inc stock and bought 48,209 units worth $1,563,736 . The most active insiders traders include Wendell P Weeks, Kenneth C Frazier a Douglas M Jr Baker. On average, Merck & Co Inc executives and independent directors trade stock every 15 days with the average trade being worth of $5,050,222. The most recent stock trade was executed by Chirfi Guindo on 5 August 2024, trading 36,901 units of MRK stock currently worth $4,250,995.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.
Merck & Co Inc executives and other stock owners filed with the SEC include: